Ilixadencel is under clinical development by Mendus and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ilixadencel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ilixadencel is under development for the prevention of hepatocellular carcinoma, gastrointestinal stromal tumor (GIST), HPV-positive or HPV-negative squamous cell carcinoma of the head and neck, non-small cell lung cancer, gastric, adenocarcinoma of the gastroesophageal Junction and colon carcinoma. The drug candidate is administered intratumorally. The vaccine candidate is based on COMBIG (Combined Toll like Receptor Interferon-Gamma) platform.
The drug candidate was under development for melanoma (first and second), brain metastasis, squamous cell carcinoma of the head and neck, metastatic renal cell carcinoma (RCC), non-small cell lung cancer, gastric and gastroesophageal junction adenocarcinoma.
Mendus, formerly Immunicum, develops allogeneic and off-the-shelf cell-based therapies for treating solid tumors. The company’s product candidate ilixadencel, an intratumoral immune primer is used for the treatment of renal cell cancer, gastrointestinal stromal tumors, multiple solid tumors and kidney, liver and hepatocellular cancer. Mendus another product DCP-001 is a cancer relapse vaccine that is derived from the DCOne leukemic cell line to treat acute myeloid leukemia and ovarian cancer. The company works in partnership with academic research groups, pharmaceutical and biotech companies to develop and commercialize new therapeutics. It operates a research and development facility in Leiden, The Netherlands. Mendus is headquartered in Stockholm, Sweden.
For a complete picture of Ilixadencel’s drug-specific PTSR and LoA scores, buy the report here.